JP Morgan Chase’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.68M Sell
246,100
-424,800
-63% -$20.1M ﹤0.01% 2813
2025
Q4
$34.1M Sell
670,900
-111,300
-14% -$5.69M ﹤0.01% 1626
2025
Q3
$43.4M Buy
782,200
+733,200
+1,496% +$42.9M ﹤0.01% 1502
2025
Q2
$3.38M Sell
49,000
-461,000
-90% -$31.4M ﹤0.01% 3503
2025
Q1
$35.4M Buy
510,000
+127,900
+33% +$10.6M ﹤0.01% 1513
2024
Q4
$32.9M Buy
382,100
+319,100
+507% +$34.5M ﹤0.01% 1595
2024
Q3
$7.5M Buy
63,000
+49,000
+350% +$6.53M ﹤0.01% 2871
2024
Q2
$2M Buy
+14,000
New +$1.86M ﹤0.01% 3793
2023
Q4
Sell
-4,700
Closed -$427K 7766
2023
Q3
$427K Sell
4,700
-44,900
-91% -$3.96M ﹤0.01% 4572
2023
Q2
$4.01M Buy
+49,600
New +$4.05M ﹤0.01% 3042
2018
Q2
Sell
-113,800
Closed -$2.8M 5642
2018
Q1
$2.8M Buy
+113,800
New +$2.99M ﹤0.01% 3034

Other funds holding NVO

JP Morgan Chase's NVO Position: Q1 2026 in Review

JP Morgan Chase reduced its Novo Nordisk (NVO) stake by 21% in Q1 2026, selling an estimated $34.3M and leaving 2,808,818 shares worth $99.1M. The position accounts for 0.01% of the portfolio, ranked #989.

JP Morgan Chase first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $722M in Q1 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • JP Morgan Chase held 2,808,818 shares of Novo Nordisk worth $99.1M as of Q1 2026.
  • JP Morgan Chase sold 724,819 Novo Nordisk shares in Q1 2026, an estimated $34.3M.
  • Novo Nordisk made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #989 holding.
  • JP Morgan Chase first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • JP Morgan Chase's Novo Nordisk position peaked at $722M in Q1 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.